Therapeutic periocular vaccination with a subunit vaccine induces higher levels of herpes simplex virus-specific tear secretory immunoglobulin A than systemic vaccination and provides protection against recurrent spontaneous ocular shedding of virus in latently infected rabbits

Virology

Volumn 252, Issue 1, 1998, Pages 200-209

  Nesburn, Anthony B ^a,b   Burke, Rae Lyn ^c   Ghiasi, Homayon ^a,b   Slanina, Susan M ^a   Wechsler, Steven L ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Corneal disease; HSV 1; Latency; Recurrent disease; Vaccine

Indexed keywords

SECRETORY IMMUNOGLOBULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE TARGETING; HERPES SIMPLEX VIRUS; IMMUNE RESPONSE; LATENT VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RABBIT; RECURRENT INFECTION; STROMA CELL; VACCINATION; VIRUS CULTURE; VIRUS SHEDDING;

ANIMALIA; DNA VIRUSES; HERPES; HUMAN HERPESVIRUS 1; ORYCTOLAGUS CUNICULUS;

EID: 0032488254     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1998.9454     Document Type: Article

References (31)

1. Foster C. S., Sandstrom I. K., Wells P. A., Thompson P., Daigle J., Opremcak E. M. Immunomodulation of experimental murine herpes simplex keratitis: II. Glycoprotein D protection. Curr. Eye Res. 7:1988;1051-1061.
2. Ghiasi H., Bahri S., Nesburn A. B., Wechsler S. L. Protection against herpes simplex virus-induced eye disease after vaccination with seven individually expressed herpes simplex virus 1 glycoproteins. Invest. Ophthalmol. Vis. Sci. 36:1995;1352-1360.
3. Ghiasi H., Kaiwar R., Nesburn A. B., Slanina S., Wechsler S. L. Baculovirus-expressed glycoprotein E (gE) of herpes simplex virus type-1 (HSV-1) protects mice against lethal intraperitoneal and lethal ocular HSV-1 challenge. Virology. 188:1992;469-476.
4. Ghiasi H., Kaiwar R., Nesburn A. B., Slanina S., Wechsler S. L. Expression of seven herpes simplex virus type 1 glycoproteins (gB, gC, gD, gE, gG, gH, and gI): Comparative protection against lethal challenge in mice. J. Virol. 68:1994;2118-2126.
5. Ghiasi H., Nesburn A. B., Wechsler S. L. Vaccination with a cocktail of seven recombinantly expressed HSV-1 glycoproteins protects against ocular HSV-1 challenge more efficiently than vaccination with any individual glycoprotein. Vaccine. 14:1996;107-112.
6. Heiligenhaus A., Berra A., Dutt J. E., Zhao T. Z., Wells P. A., Foster C. S. T-cell-induced prevention of HSV-1 keratitis by immunization with the synthetic peptide of glycoprotein D. Ophthalmologe. 91:1994;608-616.
7. Heiligenhaus A., Wells P. A., Foster C. S. Immunisation against HSV-1 keratitis with a synthetic gD peptide. Eye. 9:1995;89-95.
8. Inoue Y., Ohashi Y., Shimomura Y., Manabe R., Yamada M., Ueda S., Kato S. Herpes simplex virus glycoprotein D: Protective immunity against murine herpetic keratitis. Invest. Ophthalmol. Vis. Sci. 31:1990;411-418.
9. Irie H., Shimeld C., Williams N., Hill T. Protection against ocular and cutaneous infection with herpes simplex virus type 1 by intragastric immunization with live virus. J. Gen. Virol. 74:1993;1357-1362.
10. Keadle T. L., Laycock K. A., Miller J. K., Hook K. K., Fenoglio E. D., Francotte M., Slaoui M., Stuart P. M., Pepose J. S. Efficacy of a recombinant glycoprotein D subunit vaccine on the development of primary and recurrent ocular infection with herpes simplex virus type 1 in mice. J. Infect. Dis. 176:1997;331-338.
11. Langenberg A. G., Burke R. L., Adair S. F., Sekulovich R., Tigges M., Dekker C. L., Corey L. A recombinant glycoprotein vaccine for herpes simplex virus type 2: Safety and immunogenicity [corrected] [published erratum appears inAnn. Intern. Med. Ann. Intern. Med. 122:1995;889-898.
12. Malaty R., Gebhardt B. M., Franklin R. M. HSV-specific IgA from tears blocks virus attachment to the cell membrane. Curr. Eye Res. 7:1988;313-320.
13. Mertz G. J., Ashley R., Burke R. L., Benedetti J., Critchlow C., Jones C. C., Corey L. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. J. Infect. Dis. 161:1990;653-660.
14. Morrison L. A., Knipe D. M. Mechanisms of immunization with a replication-defective mutant of herpes simplex virus 1. Virology. 220:1996;402-413.
15. Nesburn A. B. Report of the Corneal Disease Panel: Vision Research: A National Plan 1983-1987. 1983;C.V. Mosby, St. Louis.
16. Nesburn A. B., Burke R. L., Ghiasi H., Slanina S., Bahri S., Wechsler S. L. Vaccine therapy for ocular herpes simplex virus (HSV) infection: Periocular vaccination reduces spontaneous ocular HSV type 1 shedding in latently infected rabbits. J. Virol. 68:1994;5084-5092.
17. Nesburn A. B., Burke R. L., Ghiasi H., Slanina S. M., Wechsler S. L. A therapeutic vaccine that reduces recurrent herpes simplex virus type 1 corneal disease. Invest. Ophthal. Vis. Sci. 39:1998a;1163-1170.
18. Nesburn A. B., Ghiasi H., Wechsler S. L. Ocular safety and efficacy of an HSV-1 gD vaccine during primary and latent infection. Invest. Ophthalmol. Vis. Sci. 31:1990;1497-1502.
19. Nesburn A. B., Robinson C., Dickinson R. Adenine arabinoside effect on experimental idoxuridine-resistant herpes simplex infection. Invest. Ophthalmol. 13:1974;302-304.
20. Nesburn A. B., Slanina S. M., Burke R. L., Ghiasi H., Bahri S., Wechsler S. L. Local periocular vaccination protects against eye disease more effectively than systemic vaccination following primary ocular herpes simplex virus infection in rabbits. J. Virol. 72:1998b;7715-7721.
21. Newell C. K., Martin S., Sendele D., Mercadal C. M., Rouse B. T. Herpes simplex virus-induced stromal keratitis: Role of T-lymphocyte subsets in immunopathology. J. Virol. 63:1989;769-775.
22. Perng G. C., Dunkel E. C., Geary P. A., Slanina S. M., Ghiasi H., Kaiwar R., Nesburn A. B., Wechsler S. L. The latency-associated transcript gene of herpes simplex virus type 1 (HSV-1) is required for efficient in vivo spontaneous reactivation of HSV-1 from latency. J. Virol. 68:1994;8045-8055.
23. Perng G. C., Ghiasi H., Slanina S. M., Nesburn A. B., Wechsler S. L. The spontaneous reactivation function of the herpes simplex virus type 1 LAT gene resides completely within the first 1.5 kilobases of the 8.3-kilobase primary transcript. J. Virol. 70:1996a;976-984.
24. Perng G. C., Slanina S. M., Ghiasi H., Nesburn A. B., Wechsler S. L. A 371-nucleotide region between the herpes simplex virus type 1 (HSV-1) LAT promoter and the 2-kilobase LAT is not essential for efficient spontaneous reactivation of latent HSV-1. J. Virol. 70:1996b;2014-2018.
25. Rouse B. T., Norley S., Martin S. Antiviral cytotoxic T lymphocyte induction and vaccination. Rev. Infect. Dis. 10:1988;16-33.
26. Smith R. E., McDonald H. R., Nesburn A. B., Minckler D. S. Penetrating keratoplasty: Changing indications, 1947 to 1978. Arch. Ophthalmol. 98:1980;1226-1229.
27. Straus S. E., Corey L., Burke R. L., Savarese B., Barnum G., Krause P. R., Kost R. G., Meier J. L., Sekulovich R., Adair S. F. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet. 343:1994;1460-1463.
28. Straus S. E., Savarese B., Tigges M., Freifeld A. G., Krause P. R., Margolis D. M., Meier J. L., Paar D. P., Adair S. F., Dina D. Induction and enhancement of immune responses to herpes simplex virus type 2 in humans by use of a recombinant glycoprotein D vaccine. J. Infect. Dis. 167:1993;1045-1052.
29. Straus S. E., Wald A., Kost R. G., McKenzie R., Langenberg A. G., Hohman P., Lekstrom J., Cox E., Nakamura M., Sekulovich R., Izu A., Dekker C., Corey L. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: Results of a placebo- controlled vaccine trial. J. Infect. Dis. 176:1997;1129-1134.
30. Sullivan D. A. Ocular mucosal immunity. Handbook of Mucosal Immunity. 1994;Academic Press, San Diego. p. 569-597.
31. Walker J., Laycock K., Pepose J., Leib D. Postexposure vaccination with a virion host shutoff defective mutant reduces UV-B radiation-induced ocular herpes virus shedding in mice. Vaccine. 16:1998;6-8.